These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

588 related items for PubMed ID: 21797104

  • 21. Assessment of Interleukin-17A, Interleukin-10 and Transforming Growth Factor-Beta1 Serum Titers in Relapsing Remitting Multiple Sclerosis Patients Treated with Avonex, Possible Biomarkers for Treatment Response.
    Balasa R, Maier S, Voidazan S, Hutanu A, Bajko Z, Motataianu A, Tilea B, Tiu C.
    CNS Neurol Disord Drug Targets; 2017; 16(1):93-101. PubMed ID: 27306062
    [Abstract] [Full Text] [Related]

  • 22. Interferon-beta 1b treatment decreases tumor necrosis factor-alpha and increases interleukin-6 production in multiple sclerosis.
    Brod SA, Marshall GD, Henninger EM, Sriram S, Khan M, Wolinsky JS.
    Neurology; 1996 Jun; 46(6):1633-8. PubMed ID: 8649562
    [Abstract] [Full Text] [Related]

  • 23. Cytokine profile in relapsing‑remitting multiple sclerosis patients and the association between progression and activity of the disease.
    Kallaur AP, Oliveira SR, Colado Simão AN, Delicato de Almeida ER, Kaminami Morimoto H, Lopes J, de Carvalho Jennings Pereira WL, Marques Andrade R, Muliterno Pelegrino L, Donizete Borelli S, Kaimen-Maciel DR, Reiche EM.
    Mol Med Rep; 2013 Mar; 7(3):1010-20. PubMed ID: 23292766
    [Abstract] [Full Text] [Related]

  • 24. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.
    Nikfar S, Rahimi R, Abdollahi M.
    Clin Ther; 2010 Oct; 32(11):1871-88. PubMed ID: 21095482
    [Abstract] [Full Text] [Related]

  • 25. Multiple sclerosis: levels of interleukin-10-secreting blood mononuclear cells are low in untreated patients but augmented during interferon-beta-1b treatment.
    Ozenci V, Kouwenhoven M, Huang YM, Xiao B, Kivisäkk P, Fredrikson S, Link H.
    Scand J Immunol; 1999 May; 49(5):554-61. PubMed ID: 10320650
    [Abstract] [Full Text] [Related]

  • 26. Serum cytokine levels do not correlate with disease activity and severity assessed by brain MRI in multiple sclerosis.
    Kraus J, Kuehne BS, Tofighi J, Frielinghaus P, Stolz E, Blaes F, Laske C, Engelhardt B, Traupe H, Kaps M, Oschmann P.
    Acta Neurol Scand; 2002 Apr; 105(4):300-8. PubMed ID: 11939943
    [Abstract] [Full Text] [Related]

  • 27. Interleukins 17 and 10 in a sample of Egyptian relapsing remitting multiple sclerosis patients.
    Tawfik TZ, Gad AH, Mehaney DA, El Nahrery E, Shehata HS, Hashem H, Ghaffar NFA, Shalaby N.
    J Neurol Sci; 2016 Oct 15; 369():36-38. PubMed ID: 27653861
    [Abstract] [Full Text] [Related]

  • 28. [Clinical assessment of the course of relapsing-remitting multiple sclerosis in patients treated with interferon beta].
    Pokryszko-Dragan A, Bilińska M, Gruszka E, Dubik-Jezierzańska M.
    Pol Merkur Lekarski; 2005 Nov 15; 19(113):654-8. PubMed ID: 16498805
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Effects of interferon β-1a and interferon β-1b monotherapies on selected serum cytokines and nitrite levels in patients with relapsing-remitting multiple sclerosis: a 3-year longitudinal study.
    Stępień A, Chalimoniuk M, Lubina-Dąbrowska N, Chrapusta SJ, Galbo H, Langfort J.
    Neuroimmunomodulation; 2013 Nov 15; 20(4):213-22. PubMed ID: 23711618
    [Abstract] [Full Text] [Related]

  • 31. Female sex hormones and cytokine secretion in women with multiple sclerosis.
    Trenova AG, Slavov GS, Manova MG, Kostadinova II, Vasileva TV.
    Neurol Res; 2013 Jan 15; 35(1):95-9. PubMed ID: 23317804
    [Abstract] [Full Text] [Related]

  • 32. Acute interferon beta-1b administration alters hypothalamic-pituitary-adrenal axis activity, plasma cytokines and leukocyte distribution in healthy subjects.
    Goebel MU, Baase J, Pithan V, Exton M, Saller B, Schedlowski M, Limmroth V.
    Psychoneuroendocrinology; 2002 Nov 15; 27(8):881-92. PubMed ID: 12383450
    [Abstract] [Full Text] [Related]

  • 33. RANTES production and expression is reduced in relapsing-remitting multiple sclerosis patients treated with interferon-beta-1b.
    Iarlori C, Reale M, Lugaresi A, De Luca G, Bonanni L, Di Iorio A, Feliciani C, Conti P, Gambi D.
    J Neuroimmunol; 2000 Jul 10; 107(1):100-7. PubMed ID: 10808056
    [Abstract] [Full Text] [Related]

  • 34. Cytokine patterns after therapy with Avonex®, Rebif®, Betaferon® and CinnoVex™ in relapsing-remitting multiple sclerosis in Iranian patients.
    Arababadi MK, Mosavi R, Khorramdelazad H, Yaghini N, Zarandi ER, Araste M, Pourali R, Nekhei Z, Kennedy D.
    Biomark Med; 2010 Oct 10; 4(5):755-9. PubMed ID: 20945990
    [Abstract] [Full Text] [Related]

  • 35. Benign multiple sclerosis is characterized by a stable neuroimmunologic network.
    Haase CG, Faustmann PM.
    Neuroimmunomodulation; 2004 Oct 10; 11(4):273-7. PubMed ID: 15249735
    [Abstract] [Full Text] [Related]

  • 36. Impact of interferon β-1b, interferon β-1a and fingolimod therapies on serum interleukins-22, 32α and 34 concentrations in patients with relapsing-remitting multiple sclerosis.
    Abdel-Dayem MA, Shaker ME, Gameil NM.
    J Neuroimmunol; 2019 Dec 15; 337():577062. PubMed ID: 31521828
    [Abstract] [Full Text] [Related]

  • 37. Efficacy of fish oil on serum of TNF α , IL-1 β , and IL-6 oxidative stress markers in multiple sclerosis treated with interferon beta-1b.
    Ramirez-Ramirez V, Macias-Islas MA, Ortiz GG, Pacheco-Moises F, Torres-Sanchez ED, Sorto-Gomez TE, Cruz-Ramos JA, Orozco-Aviña G, Celis de la Rosa AJ.
    Oxid Med Cell Longev; 2013 Dec 15; 2013():709493. PubMed ID: 23861993
    [Abstract] [Full Text] [Related]

  • 38. Multiple sclerosis is associated with an imbalance between tumour necrosis factor-alpha (TNF-alpha)- and IL-10-secreting blood cells that is corrected by interferon-beta (IFN-beta) treatment.
    Ozenci V, Kouwenhoven M, Huang YM, Kivisäkk P, Link H.
    Clin Exp Immunol; 2000 Apr 15; 120(1):147-53. PubMed ID: 10759776
    [Abstract] [Full Text] [Related]

  • 39. Neutralizing and binding anti-interferon-beta (IFN-beta) antibodies. A comparison between IFN-beta-1a and IFN-beta-1b treatment in multiple sclerosis.
    Kivisäkk P, Alm GV, Fredrikson S, Link H.
    Eur J Neurol; 2000 Jan 15; 7(1):27-34. PubMed ID: 10809912
    [Abstract] [Full Text] [Related]

  • 40. Serum Levels of Biomarkers of Immune Activation and Associations With Neurological Impairment in Relapsing-Remitting Multiple Sclerosis Patients During Remission.
    Witkowska AM, Socha K, Kochanowicz J, Karpińska E, Jakoniuk M, Zujko ME, Wilkiel M, Borawska MH, Mariak Z.
    Biol Res Nurs; 2016 Jan 15; 18(1):113-9. PubMed ID: 25911236
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 30.